Search results
Cornerstone Advisors LLC Sells 7,098 Shares of Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 5 days agoCornerstone Advisors LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities ...
Research shows linked biological pathways driving skin inflammation
Medical Xpress· 6 days agoInflammation is the body's natural response to irritation and infection, but when out of control, it...
Potential Precursor Lesion to Adrenal Tumors Identified
Medscape· 4 days agoCortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules...
Guselkumab Continues Winning Streak in Crohn's Disease
MedPage Today· 5 days agoInduction and maintenance treatment with guselkumab (Tremfya) demonstrated its safety and efficacy...
AbbVie (NYSE:ABBV) vs. Cosmo Pharmaceuticals (OTC:CMOPF) Head to Head Review
ETF DAILY NEWS· 2 days agoAbbVie (NYSE:ABBV – Get Free Report) and Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses ...
Amgen Inc. (NASDAQ:AMGN) Holdings Cut by Panagora Asset Management Inc.
ETF DAILY NEWS· 6 days agoPanagora Asset Management Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure ...
Studies Show Linked Biological Pathways Driving Skin Inflammation
WFRV 5 Green Bay· 6 days agoA certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies ...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 6 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
Johnson & Johnson (NYSE:JNJ) Trading Down 1.1%
ETF DAILY NEWS· 1 day agoShares of Johnson & Johnson (NYSE:JNJ – Get Free Report) were down 1.1% during mid-day trading on Thursday . The company traded as low as $151.70 and last traded at $151.81. Approximately 1,428,737 ...
AltruBio, after tweaking checkpoint drug, raises $225M for midphase ulcerative colitis program
FierceBiotech· 5 days agoAltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis ...